The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.
Moon Ki Choi
No relevant relationships to disclose
Jung Yong Hong
No relevant relationships to disclose
Won Jin Chang
No relevant relationships to disclose
Moonjin Kim
No relevant relationships to disclose
Sungmin Kim
No relevant relationships to disclose
Hyun Ae Jung
No relevant relationships to disclose
Sung Hee Lim
No relevant relationships to disclose
Ji Yun Lee
No relevant relationships to disclose
Ingu Do
No relevant relationships to disclose
Yoon-La Choi
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Jin Seok Ahn
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose